Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS03-adjuvanted low-dose trivalent inactivated influenza vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The AS03-adjuvanted low-dose trivalent inactivated influenza vaccine is an investigational seasonal influenza vaccine developed by GSK. It consists of a trivalent inactivated split-virion influenza vaccine (TIV) containing reduced doses of hemagglutinin (HA) antigens from three influenza strains (A/H1N1, A/H3N2, and B), combined with the proprietary AS03 Adjuvant System. AS03 is an oil-in-water emulsion containing squalene, alpha-tocopherol (vitamin E), and polysorbate-80, designed to enhance the immune response and allow for antigen dose-sparing. The vaccine aims to induce robust humoral and cellular immunity, specifically targeting hemagglutinin to prevent seasonal influenza in adults.
- Other names
- AS03-adjuvanted TIVAS-03-adjuvanted TIVAS 03-adjuvanted TIVlow-dose AS03-adjuvanted trivalent inactivated influenza vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on AS03-adjuvanted low-dose trivalent inactivated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS03-adjuvanted low-dose trivalent inactivated influenza vaccine.